方法：对343例343眼前部缺血性视神经病变患者采用肌肉注射鼠NGF 30μg qd，连续注射3wk，同时给予扩血管药、神经营养剂进行治疗。记录治疗前后的矫正logMAR视力、视野平均缺损值(mean deviation，MD)、视诱发电位潜伏期(pattern visual evoked potential，P-VEP)等指标并进行分析和统计。对治疗过程中的不良反应进行统计以评价其安全性。

结果：应用NGF治疗后，患者的视力较治疗前显著提高，视野MD值较治疗前显著降低，P-VEP显示潜伏期较治疗前显著缩短，差异具有统计学意义(P<0.05)。本研究共发生实验室指标不良事件18例，发生率为5.25%。

结论：鼠NGF联合扩血管药和神经营养剂治疗前部缺血性视神经病变疗效满意，不良反应少。

METHODS:A total of 343 eyes of 343 patients with anterior ischemic optic neuropathy were treated with mouse NGF by the dosage of 30μg qd and continuous injected for three weeks, at the same time given expanding vascular medicine and neurotrophic agent. Corrected LogMar visual acuity, visual field mean deviation(MD)values and pattern visual evoked potential(P-VEP)were recorded and analyzed. The adverse reactions in the course of treatment were analyzed in order to evaluate the safety of this method.

RESULTS: The patient's vision after treatment were significantly increased compared with that before treatment, MD of visual field and P-VEP display incubation period after treatment were significantly lowered compared with that before treatment, the difference were statistically significant(P<0.05). There were 18 cases of adverse events in laboratory indicators in this study, and the incidence rate was 5.25%.

CONCLUSION: Mouse nerve growth factor combined with vasodilators and neurotrophin for the treatment of anterior ischemic optic neuropathy had satisfaction efficacy and safety.